Consequently, targeting the nucleotidase activity only may not be enough to fully block the tumor‐promoting effect of CD73 in PDAC.[13, 49] Moreover, anti‐CD73 mAb treatment may also result in the internalization of CD73, which may further increase the concentration of intracellular CD73.[50] As a result, an optimal CD73 targeting strategy should also consider the intracellular and nucleotidase‐independent functions of CD73. Here, NT5E is linked to neoplasm.